Elanco Animal Health Incorporated (ELAN)
| Market Cap | 12.24B +42.0% |
| Revenue (ttm) | 5.02B +12.0% |
| Net Income | -199.00M |
| EPS | -0.41 |
| Shares Out | 499.62M |
| PE Ratio | n/a |
| Forward PE | 20.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,718,004 |
| Open | 24.20 |
| Previous Close | 24.42 |
| Day's Range | 24.00 - 24.71 |
| 52-Week Range | 17.11 - 27.98 |
| Beta | 1.68 |
| Analysts | Strong Buy |
| Price Target | 31.21 (+27.39%) |
| Earnings Date | Aug 5, 2026 |
About ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal fam... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for ELAN stock is "Strong Buy." The 12-month stock price target is $31.21, which is an increase of 27.39% from the latest price.
News
Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility
The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipeline INDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ --...
Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species
Vigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical experts Emergency Use Authorization for Elanco's CLiK Extra pro...
Elanco CEO on Boosted Forecast, Surge in Tick Bites
Elanco Animal Health President and CEO Jeff Simmons discusses what's behind the company's increased profit and revenue forecasts. Speaking on "Bloomberg The Close," Simmons also comments on the recent...
Elanco Animal Health Earnings Call Transcript: Q2 2026
Q2 2026 saw 8% organic revenue growth, margin expansion, and strong innovation-driven gains, especially from Zenrelia and Credelio Quattro. Full-year guidance was raised for revenue, EBITDA, and EPS, with continued investment in launches and productivity initiatives.
Elanco Animal Health Earnings release: Q2 2026
Elanco Animal Health released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Elanco Animal Health Slides: Q2 2026
Elanco Animal Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Elanco Animal Health Quarterly report: Q2 2026
Elanco Animal Health has published its Q2 2026 quarterly earnings report on August 5, 2026.
Elanco Animal Health Reports Second Quarter 2026 Results
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2026 Financial Results: Revenue of $1,368 million, an increase of 10% year-over-year; 8% or...
Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs
Report highlights Elanco's impact through innovation, expanded access to animal care, a stronger and more sustainable food system and investment in people and communities INDIANAPOLIS, July 31, 2026 /...
Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets)
Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro: Kills existing black-legged tick (Ixodes scapularis) infestations faster2 than leading competitors, within just 8 hours...
Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement
INDIANAPOLIS, July 8, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct...
Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health
New corporate venture capital platform will invest to advance therapeutics, technologies and One Health solutions INDIANAPOLIS, June 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: E...
Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs
TruCan Ultra Lyme-L4 is the first and only 1/2 mL combination vaccine protecting against both Lyme disease and leptospirosis, all in a low-volume dose By combining two injections into one, the vaccine...
Elanco CEO on rolling out New World screwworm vaccine: 'We're prepared'
Jeffrey Simmons, Elanco, joins 'Closing Bell Overtime' to talk producing a vaccine for the New World Screwworm infection in cattle in the U.S.
Confirmed screwworm case in Texas sends two biotech stocks higher
Options volume is surging for Zoetis as traders look for potential stock market winners in light of a screwworm case in Texas.
Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm
Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States New World screwworm has officially reached the United States, with the first conf...
New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience
INDIANAPOLIS, June 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a global leader in animal health, today released new consumer research showing pet owners continue to priorit...
Elanco Animal Health Transcript: 46th Annual William Blair Growth Stock Conference
The company is leveraging a robust innovation pipeline and diversified global presence to drive mid-single-digit revenue growth, high single-digit EBITDA, and over $1 billion in free cash flow through 2028. U.S. pet health is a key growth area, with new product launches and resilient consumer demand supporting strong financial guidance.
Elanco Animal Health Slides: 46th Annual William Blair Growth Stock Conference
Elanco Animal Health has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Elanco Animal Health Transcript: Stifel Jaws & Paws Conference 2026
The conference highlighted robust growth in animal health, driven by innovation in pet and farm segments, resilient pricing, and strong product launches like Zenrelia and Befrena. Strategic focus remains on operational efficiency, disciplined capital allocation, and a robust pipeline for future growth.
Elanco Animal Health Transcript: AGM 2026
The meeting highlighted strong 2025 results, with growth in both pet and farm animal segments and innovation driving $1.2 billion in revenue. All board nominees and proposals were approved, and the company outlined plans for new blockbuster products and continued margin improvement.
Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market
Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics today Befrena is effective for the treatment of...
Elanco to Participate in Upcoming Investor Conferences
INDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Wednesday, May 27, Jeff ...
'WE WILL BE PREPARED': Inside efforts to stop screwworm outbreak
Elanco Animal Health CEO Jeff Simmons discusses response to screwworm outbreak concerns on 'The Claman Countdown.'
Elanco Animal Health Earnings Call Transcript: Q1 2026
Q1 2026 saw 10% organic revenue growth, outpacing guidance, with strong performance across all segments and innovation products. Full-year guidance was raised for revenue, adjusted EBITDA, and EPS, while deleveraging continues and new retail and M&A initiatives expand reach.